- First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trial
- RECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levels
- Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes
The Company has explored multiple infusion times of R327 within this study, ranging from 15-45 minutes. 4,000mg is the highest dose tested in participants in this trial. With Minimum Inhibitory Concentration (MIC) activity against bacteria already detected in existing clinical samples, increasing dose optimization becomes a pivotal exercise for regulatory compliance.
The full efficacious potential of R327 via intravenous (IV) administration will be made available at the completion of this trial in line with the study protocol.
More information on this trial can be found at the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12623000448640.
About
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (
mfitzhugh@lifescicomms.com
Investor Relations (
gvanrenterghem@lifesciadvisors.com
Source:
2024 GlobeNewswire, Inc., source